Consumption of oral anticancer drugs in Norway compared by different units of measurements – introduction of new DDDs
DOI:
https://doi.org/10.5324/nje.v29i1-2.4041Sammendrag
Background: Antineoplastic agents (ATC group L01) have not been assigned DDDs due to highly interindividual
variation in dosages. Consumption data has therefore been presented in other measurement units such as grams of active ingredient. However, the protein kinase inhibitors (PKIs) are a rapidly growing drug group that was introduced to the market recently and are administered orally in a fixed dose. DDDs were therefore established for the PKIs in 2020. In this study we aim to assess whether the newly assigned DDDs would better express drug utilisation patterns in Norway than the current units of measurement.
Methods: Sales data for PKIs (ATC level L01E) by grams, cost, units and packages for 2019 were collected
from the Norwegian Drug Wholesales Statistics and data on number of prescriptions and prevalence for 2019
were collected from the Norwegian Prescription Database (NorPD). DDDs were calculated by applying the
values of the new DDDs.
Results: The proportions of the different substances varied according to the unit of measurement. DDDs and
packages had the highest similarity and correlated better than grams with the prevalence of use in the
Norwegian population. BCR-ABL tyrosine kinase inhibitors was the largest group accounting for 31% of
the total consumption (DDD/1000 inhabitants/day) and imatinib was the most sold PKI in all units of measurement except cost.
Conclusions: Using an international agreed unit of measurement gives reliability to the study result. Assignment of DDDs to PKIs will improve the quality of drug utilisation studies in this area.
Downloads
Nedlastinger
Publisert
Hvordan referere
Utgave
Seksjon
Lisens
Opphavsrett 2021 Kristine Olsen
Dette verket er lisensiert under en Creative Commons Attribution 4.0 International Lisens.
Norsk Epidemiologi licenses all content of the journal under a Creative Commons Attribution (CC-BY) licence. This means, among other things, that anyone is free to copy and distribute the content, as long as they give proper credit to the author(s) and the journal. For further information, see Creative Commons website for human readable or lawyer readable versions.
Authors who publish with this journal agree to the following terms:
1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
